<?xml version="1.0" encoding="UTF-8"?>
<STUDY_SET>
<STUDY accession="ERP104577" alias="ena-STUDY-INRA-META-03-10-2017-10:54:45:663-117" center_name="Institut National pour la Recherche Agronomique (FRANCE)">
     <IDENTIFIERS>
          <PRIMARY_ID>ERP104577</PRIMARY_ID>
          <SECONDARY_ID>PRJEB22863</SECONDARY_ID>
          <SUBMITTER_ID namespace="Institut National pour la Recherche Agronomique (FRANCE)">ena-STUDY-INRA-META-03-10-2017-10:54:45:663-117</SUBMITTER_ID>
     </IDENTIFIERS>
     <DESCRIPTOR>
          <STUDY_TITLE>Gut mictobiota composition correlation with the clinical outcome of NSCLC and RCC patients treated with anti-PD-1 mAB</STUDY_TITLE>
          <STUDY_ABSTRACT>Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizeable minority of cancer patients. Here, we show that primary resistance to ICI can be due to an abnormal gut microbiota. Antibiotics (ATB) inhibited the clinical benefit of ICI in advanced cancer patients. Fecal microbiota transplantation (FMT) from cancer patients who responded to ICI (but not from non-responding patients) into germ-free or ATB-treated mice ameliorated the antitumor effects of PD-1 blockade. Metagenomics of patient stools at diagnosis revealed correlations between clinical responses to ICI and the relative abundance of Akkermansia muciniphila. Oral supplementation with A. muciniphila post-FMT with non-responder feces restored the efficacy of PD-1 blockade in an IL-12-dependent manner, by increasing the recruitment of CCR9+CXCR3+CD4+ T lymphocytes into tumor beds.</STUDY_ABSTRACT>
          <STUDY_DESCRIPTION>Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizeable minority of cancer patients. Here, we show that primary resistance to ICI can be due to an abnormal gut microbiota. Antibiotics (ATB) inhibited the clinical benefit of ICI in advanced cancer patients. Fecal microbiota transplantation (FMT) from cancer patients who responded to ICI (but not from non-responding patients) into germ-free or ATB-treated mice ameliorated the antitumor effects of PD-1 blockade. Metagenomics of patient stools at diagnosis revealed correlations between clinical responses to ICI and the relative abundance of Akkermansia muciniphila. Oral supplementation with A. muciniphila post-FMT with non-responder feces restored the efficacy of PD-1 blockade in an IL-12-dependent manner, by increasing the recruitment of CCR9+CXCR3+CD4+ T lymphocytes into tumor beds.</STUDY_DESCRIPTION>
          <CENTER_PROJECT_NAME>Gut mictobiota composition correlation with the clinical outcome of NSCLC and RCC patients treated with anti-PD-1 mAB</CENTER_PROJECT_NAME>
          <STUDY_TYPE existing_study_type="Other"/>
     </DESCRIPTOR>
     <STUDY_LINKS>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>PUBMED</DB>
                    <ID>29097494</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-SAMPLE</DB>
                    <ID>ERS2034069-ERS2034287</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-EXPERIMENT</DB>
                    <ID>ERX2268014-ERX2268232</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-RUN</DB>
                    <ID>ERR2213660-ERR2213743,ERR2235210-ERR2235344</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-SUBMISSION</DB>
                    <ID>ERA1108184</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-FASTQ-FILES</DB>
                    <ID><![CDATA[https://www.ebi.ac.uk/ena/portal/api/filereport?accession=ERP104577&result=read_run&fields=run_accession,fastq_ftp,fastq_md5,fastq_bytes]]></ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-SUBMITTED-FILES</DB>
                    <ID><![CDATA[https://www.ebi.ac.uk/ena/portal/api/filereport?accession=ERP104577&result=read_run&fields=run_accession,submitted_ftp,submitted_md5,submitted_bytes,submitted_format]]></ID>
               </XREF_LINK>
          </STUDY_LINK>
     </STUDY_LINKS>
     <STUDY_ATTRIBUTES>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-SPOT-COUNT</TAG>
               <VALUE>4678115987</VALUE>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-BASE-COUNT</TAG>
               <VALUE>651176116707</VALUE>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-FIRST-PUBLIC</TAG>
               <VALUE>2017-11-14</VALUE>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-LAST-UPDATE</TAG>
               <VALUE>2021-10-11</VALUE>
          </STUDY_ATTRIBUTE>
     </STUDY_ATTRIBUTES>
</STUDY>
</STUDY_SET>
